Li K S, Yamashiro T, Sumie A, Terao H, Mifune K, Nishizono A
Department of Microbiology, Oita Medical University, Idaigaoka 1-1, Hasama-machi, Oita, 879-5593, Japan.
J Clin Virol. 2001 Dec;23(1-2):97-106. doi: 10.1016/s1386-6532(01)00212-8.
Emergence of anti-HBe following seroconversion of HBe antigen indicates reduced hepatitis B virus (HBV) replication in the liver and low infectivity in the natural course of infection. However, some patients show continued replication or reactivation even in the presence of anti-HBe.
To clarify the cause of HBV replication, we investigated genotype differences and mutations in the core promoter and precore region in relation to virus titer.
Using quantification of HBV DNA, nucleotide sequencing of the core promoter and precore region, and genotyping with the S gene by restriction fragment length polymorphism (RFLP), we analyzed sera of 26 anti-HBe positive carriers (28 serum samples).
Various mutations were detected including C to T point mutation at nt 1653, A to T and G to A contiguous point mutations at nt 1762 and 1764 in the core promoter region, and G to A point mutation at nt 1896 in the precore region, but no common mutations were detected that were directly related to the virus titer from earlier reported mutations. In contrast, the mean titer of genotype B virus was 1.5 x 10(5) copies per ml and that of mutant HBV of genotype C having 8 base pairs (8-bp) deletion (nt 1768-1775) in the core promoter region was 7.9 x 10(4) copies per ml (mean titer). These titers showed commonly lower than that of genotype C virus without 8-bp deletion (median titer 5.0 x 10(6) copies per ml). Transition of genotype from C to B after viral reactivation and reduction of proportion of 8-bp deletion mutant at reactivation period was observed in a patient who demonstrated exacerbation of liver dysfunction due to immunosuppressive therapy and increased viral replication.
These results confirm those of our earlier study describing low replication ability of 8-bp deletion mutant HBV in vitro, and also indicate that the presence of genotype B correlates with reduced titer of HBV.
HBe抗原血清学转换后出现抗-HBe表明在自然感染过程中,乙型肝炎病毒(HBV)在肝脏中的复制减少且传染性较低。然而,一些患者即使存在抗-HBe仍表现出持续复制或再激活。
为阐明HBV复制的原因,我们研究了与病毒载量相关的核心启动子和前核心区的基因型差异及突变情况。
通过定量HBV DNA、对核心启动子和前核心区进行核苷酸测序以及利用限制性片段长度多态性(RFLP)对S基因进行基因分型,我们分析了26例抗-HBe阳性携带者的血清(28份血清样本)。
检测到多种突变,包括核心启动子区第1653位核苷酸的C到T点突变、第1762和1764位核苷酸的A到T以及G到A连续点突变,和前核心区第1896位核苷酸的G到A点突变,但未检测到与先前报道的突变直接相关的、与病毒载量相关的常见突变。相比之下,B基因型病毒的平均载量为每毫升1.5×10⁵拷贝,核心启动子区有8个碱基对(8-bp)缺失(第1768 - 1775位核苷酸)的C基因型突变型HBV的平均载量为每毫升7.9×10⁴拷贝。这些载量通常低于无8-bp缺失的C基因型病毒(中位载量为每毫升5.0×10⁶拷贝)。在一名因免疫抑制治疗导致肝功能障碍加重且病毒复制增加的患者中,观察到病毒再激活后基因型从C转换为B以及再激活期8-bp缺失突变体比例降低的情况。
这些结果证实了我们早期研究中所描述的8-bp缺失突变型HBV在体外复制能力较低的情况,也表明B基因型的存在与HBV载量降低相关。